

Dermatologic Emergencies When to Act Fast!

ACOI Subspecialty Focused Review
May 12, 2022

Heather Layher, DO, MBA, FAAD

Objectives

- To recognize cutaneous manifestations of conditions that are considered dermatologic emergencies.
- To become familiar with the recommended work-up for various dermatologic emergencies.
- To be prepared to quickly manage dermatologic emergencies to provide patients with the best outcome.

Dermatologic Emergencies in Primary Care

- Adverse Drug Reactions

- EM Major
- SJS/TEN
- DRESS
- AGEP

- Infection Related Dermatoses

- Eczema herpeticum
- Staph scalded skin syndrome
- Rocky Mountain spotted fever
- Necrotizing fasciitis

- Immunobullous Exacerbations

- Bullous pemphigoid
- Pemphigus vulgaris

Adverse Drug Reactions

EM Major

SJS/TEN

DRESS

AGEP

Erythema Multiforme (EM) Major

- Immune mediated mucocutaneous reaction most commonly to infection
 - Cutaneous eruption in both EM minor and EM major
 - Severe mucosal eruption in EM major only
- Population – young adults
- Causes – cutaneous reaction to HSV infection (most common), mycoplasma pneumoniae (associated with severe mucosal disease), systemic medications (NSAIDS, sulfadruugs, antiepileptics, allopurinol), other infections, radiation, malignancy, autoimmune disease
- Diagnosis – clinical, histopathological via biopsy and direct immunofluorescence
- Self resolving over 4-6 weeks, recurrence possible
 - Important note – EM is not in a spectrum with SJS/TEN and therefore does not progress

Erythema Multiforme (EM) Major – Presentation

- Prodrome – fever, fatigue, malaise, myalgia
- Classic cutaneous targetoid lesions appearing within 24 hours
 - 3 rings – central dusky erythematous papule surrounded by white ring surrounded by erythematous ring
 - Develop symmetrically on acral and facial surfaces and spread centrally to trunk
 - Painful, pruritis
- Mucosal involvement
 - Oral most common – blisters become erosions with whitish pseudo-membrane
 - Ocular – keratitis, uveitis, conjunctival scarring
 - Urogenital – blisters become erosions



Erythema Multiforme (EM) Major – Management

- Mucosal involvement is what makes EM major a dermatologic emergency
 - Decreased PO intake
 - Vision loss
 - Difficulty breathing due to erosions and sloughing of mucosa → although rare, may require intubation

Erythema Multiforme (EM) Major – Management

- Mild cutaneous disease
 - Topical steroids for skin (Triamcinolone, Clobetasol), swish-and-spit steroids for mouth (Betamethasone)
 - Antihistamines
 - Oral Lidocaine swish-and-spits
- Severe mucosal disease
 - Admission – oral intake support, possibly airway support
 - Prednisone
- Treatment of cause
 - Suppressive Acyclovir/Valacyclovir (questionable benefit)
 - Remove triggering medications if medication-induced

Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)


- Acute, severe cutaneous adverse reaction most commonly to medications
- Population – any age, gender, race
 - Higher risk in HIV
- Causes –
 - Medications (most common) –
 - Antibiotics (40%) – sulfonamides, penicillins, cephalosporins
 - Other common drugs – anticonvulsants and allopurinol
 - Less common drugs – acetaminophen, NSAIDs, nevirapine
 - Infections (very rare) – CMV

SJS/TEN – Presentation

- Onset variable – within 1 week with antibiotics, few days to 3 weeks with most other drugs, up to 2 months with anticonvulsants
- Spectrum of diseases determined by % of skin involvement
 - SJS <10% TBSA >> SJS/TEN overlap 10-30% TBSA >> TEN >30% TBSA
- Prodrome – flu-like symptoms (fever, sore throat, runny nose, cough, conjunctivitis, red sore eyes, malaise and myalgias) + painful skin

SJS/TEN – Skin Presentation

- Abrupt onset of tender skin lesions starting on trunk and rapidly spreading to face and extremities over few days
 - Scalp, palms/soles – not involved
- Morphology
 - Erythematous, dusky or purpuric macules
 - Diffuse erythema
 - Targetoid or bullous (flacid)
- Skin lesions coalesce → skin sloughs in sheets → oozing red raw dermis
- Nikolsky sign – rubbing of finger on skin causes shearing of epidermis



SJS/TEN – Mucosal Presentation

- Severe mucosal involvement classic with SJS/TEN
- Oral – cheilitis, stomatitis → red crusted painful lips and mouth ulcers
- Ocular – conjunctivitis, ulceration, uveitis, photosensitivity → red sore eyes
- Genital – erosions/ulcers → urinary retention, scarring
- Respiratory – sloughing of trachea/bronchus → coughing, respiratory distress requiring intubation



SJS/TEN – Complications (Early)

- Mortality – 1-5% in SJS, 25-35% in TEN
- Dehydration
- Malnutrition
- Infection – cutaneous and hematologic
- Respiratory distress
- Gastrointestinal ulceration and perforation
- Shock, multiorgan failure

*Very low threshold for admission in SJS, absolute admission in TEN

SJS/TEN – Complications (Long-Term)

- Widespread pigment alteration
- Widespread scarring (may appear similar to burn scarring)
- Xerophthalmia, epiphora, conjunctivitis, corneal scarring, ectropion/entropion, trichiasis
- Scarring permanent loss of nails
- Phimosis (foreskin scarring), vaginal introitus scarring
- Joint contractures
- Chronic bronchitis, obstructive lung disease

SJS/TEN – Workup

- Skin biopsy can confirm
- Monitor labs – pancytopenia, transaminitis (hepatitis possible), proteinuria (renal failure possible)

- SCORTEN

1 point per criteria

- >40yo
- Malignancy
- HR >120
- >10% initial TBSA
- Urea >10mmol/L
- Glucose >14mmol/L
- Bicarbonate <20mmol/L

SCORETEN scores estimates mortality

- 0-1 – 3.2%
- 2 = 12.1%
- 3 = 35.3%
- 4 = 58.3%
- 5+ = 90%


SJS/TEN – Management

- Stop causative drug
 - Admission – ICU or burn unit
 - Nutrition replacement
 - Fluid replacement (important to place Foley early)
 - Thermoregulation
 - Pain relief
 - Airway management (intubation)
 - Skin – gentle skin care and cleaning (chlorhexidine, silver nitrate), Vaseline wraps, avoid adhesives
 - Ocular – Ophtho consult, eyedrops (lubricating, antibacterial, and steroid) to prevent ocular scarring and vision loss
 - Oral – steroid swish-and-spit, anesthetic swish-and-spit
 - Vaginal – intravaginal topical steroids to prevent vaginal scarring
- *Always monitor for cutaneous and systemic infection

SJS/TEN – Medication Management

- High dose systemic steroids during first 5 days (benefit still questionable)
- Ciclosporin may significantly reduce mortality
- Less common treatments
 - TNFa-inhibitors
 - Cyclophosphamide
 - IVIG
 - Plasmapheresis
 - GCSF

APPROACH TO THE PATIENT WITH STEVENS-JOHNSON SYNDROME OR TOXIC EPIDERMAL NECROLYSIS



Question 1

Which of the following is false regarding toxic epidermal necrolysis (TEN)?

- A. >30% of total body surface area is involved in TEN
- B. Sulfa drugs and antiepileptics are two of the most common causative agents
- C. Mortality is low at less than 5%
- D. General onset is within 3 weeks after starting causative agent

Question 2

T/F – TEN requires admission for airway support, thermal regulation, fluid monitoring and replacement, nutritional support and wound care. This is best accomplished in a burn unit or a unit familiar with managing such requirements.

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

- Acute, severe systemic adverse drug reaction
- Synonyms – drug hypersensitivity syndrome (DHS), drug-induced hypersensitivity syndrome (DIHS)
- Population – adults, M=F
- Causes – anticonvulsants (carbamazepine, phenobarbital, phenytoin), allopurinol, olanzapine, sulphonamide antibiotics
 - Onset – within 2 weeks with antibiotics, greater than 2 weeks with anticonvulsants and allopurinol
 - Anticonvulsants – estimated 1:10,000 patients
 - Allopurinol – risk increases in CKD and concomitant thiazide diuretics

DRESS – Skin Presentation

- Symptoms develop over several days
- Fever of 38-40C followed by widespread rash
 - Morbilliform eruption
 - Facial edema
 - Mucosal involvement less common

*Severity of cutaneous eruption does not correlate with severity of systemic involvement



DRESS – Systemic Presentation

- Systemic symptoms may continue to worsen and persist for several weeks even after drug discontinuation
 - Generalized lymphadenopathy*
 - Atypical lymphocytes*, eosinophilia*, leukocytosis, thrombocytopenia, anemia
 - Transaminitis*, hepatitis, liver failure
 - Myocarditis*, pericarditis
 - Thyroiditis* (autoimmune)
 - Interstitial nephritis (mild and rare)
 - Interstitial pneumonitis, pleuritis, pneumonia, ARDS
 - Meningitis, encephalitis, polyneuritis
 - Gastroenteritis, pancreatitis, GI bleeding, acute colitis
 - Myositis
 - Uveitis

DRESS – Diagnosis

- Diagnosis determined using regiSCAR scoring system
- Final score –
 - <2 – not DRESS
 - 2-3 – possible DRESS
 - 4-5 – probable DRESS
 - >5 – definite DRESS

RegiSCAR SCORING SYSTEM FOR DRESS			
Criteria	No	Yes	Unknown/unclassifiable
Fever ($\geq 38.5^{\circ}\text{C}$)	-1	0	-1
Lymphadenopathy (≥ 2 sites; > 1 cm)	0	1	0
Circulating atypical lymphocytes	0	1	0
Peripheral hypereosinophilia	0		0
0.7–1.499 $\times 10^9/\text{L}$ - or - 10–19.9%*		1	
$\geq 1.5 \times 10^9/\text{L}$ - or - $\geq 20\%$ *		2	
Skin involvement			
• Extent of cutaneous eruption $> 50\%$ BSA	0	1	0
• Cutaneous eruption suggestive of DRESS**	-1	1	0
• Biopsy suggests DRESS	-1	0	0
Internal organs involved†			
One		1	
Two or more		2	
Resolution in ≥ 15 days	-1	0	-1
Laboratory results negative for at least three of the following (and none positive): (1) ANA; (2) blood cultures; (3) HAV/HBV/HCV serology; and (4) <i>Chlamydia</i> and <i>Mycoplasma</i> serology	0	1	0
Final score: < 2, no case; 2–3, possible case; 4–5, probable case; > 5, definite case			

DRESS – Complications

- Delayed autoimmune thyroiditis
 - TSH/T4 during admission, at 6-12 weeks, as well as at 1 and 2 years post-DRESS
- Fulminant myocarditis
 - Echo during admission and at 3 weeks post-DRESS
- Hemophagocytic syndrome
- Hepatic failure
- Multiorgan failure

DRESS – Management

- Admission
- Withdrawal of causative drug
- Systemic workup

Basic laboratory screening during the acute phase with recommended repetitive tests *in italics*[△]

- *CBC with differential, platelet count*, peripheral smear for atypical lymphocytes
- *BUN, creatinine, urinalysis*, spot urine for protein : creatinine ratio^{*}
- *LFTs, creatine kinase (CK)*, lipase, CRP
- *TSH, free T4* (repeat at 3 months, 1 year, and 2 years)
- Fasting glucose (in anticipation of systemic corticosteroids)

Additional testing

- ECG, troponin T, baseline echocardiogram
- Quantitative PCR for HHV-6, HHV-7, EBV, CMV
- Wright stain of urine for eosinophilia (prior to instituting corticosteroids)
- ANA, blood cultures (exclusion criteria in RegiSCAR scoring system)
- If hemophagocytic lymphohistiocytosis suspected (see [Ch. 91](#))^{**}, ferritin, triglycerides, LDH, BM examination

Further testing based upon laboratory abnormalities or signs and symptoms^{**}

- Liver – PT, PTT, albumin
- Renal – albumin, renal ultrasound (if laboratory abnormalities)
- Cardiac – ECG, troponin T, echocardiogram
- Neurologic – brain MRI
- Pulmonary – CXR, PFTs
- Gastrointestinal – endoscopy

[△]Testing is more frequent during the acute phase (e.g. twice weekly) with frequency also a reflection of disease severity. Longitudinal evaluation is recommended for at least one year.

^{*}Allows for immediate assessment for proteinuria.

^{**}Including during longitudinal evaluation.

DRESS – Management

- Skin – wound care and emollients, topical steroids, oral antihistamines
- Systemic Prednisone in cases with severe systemic involvement
- Other systemic therapies – ciclosporin, IVIG, plasmapheresis, cyclophosphamide, mycophenolate, rituximab
- Fluid, electrolyte and calorie management in severe systemic cases

Question 3

Which of the following is not a potential finding in drug reaction with eosinophilia and systemic symptoms (DRESS)?

- A. Centrofacial erythema and edema
- B. Lymphadenopathy
- C. Leukocytosis
- D. Eosinophilia
- E. Elevated LFTs
- F. All of the above are potential findings in DRESS

Question 4

Which of the following is recommended in the management of drug reaction with eosinophilia and systemic symptoms (DRESS)?


- A. Admission to ICU or burn unit, withdrawal of causative agent, and in the setting of lab workup indicative of end-organ involvement, initiation of systemic steroids at at least 1mg/kg/day
- B. LFTs, PTT/PT/INR and hepatitis panel due to risk of fulminant hepatitis
- C. EKG and echocardiogram due to risk of myocarditis and heart failure during admission and within 3 months after recovery
- D. TSH/T4 due to risk of autoimmune thyroiditis during admission and 6 weeks and 3 months after recovery
- E. BUN/Cr, urinalysis, possible renal US due to risk of renal failure
- F. All of the above are recommended

Acute Generalized Exanthematous Pustulosis (AGEP)

- Acute cutaneous eruption due to medication
- Population – all ages and genders
- Causes – beta-lactam antibiotics (penicillins, cephalosporins, quinolones), tetracyclines, sulfonamides, terbinafine, calcium channel blockers, hydroxychloroquine, carbamazepine, acetaminophen, viral infection (less common – EBV, HBV, CMV, enterovirus, adenovirus)

AGEP – Presentation

- Rapid onset
- Patchy erythema with tiny sterile pustules
 - Starts in armpits/groin then becomes more widespread, but remains more prominent in skin folds
- Facial swelling possible
- Oral lesions less common (~20%)
- Fever, malaise possible, but patient is generally not unwell
- Persists for 1-2 weeks followed by focal superficial skin desquamation
- Systemic involvement uncommon (~10%) – hepatic, renal, pulmonary, hematologic



AGEP – Management

- Typically admitted, although less severe cases can be managed outpatient
- Discontinue causative drug
- Topical steroids, oral antihistamines, wound care and emollients, topical analgesics
 - Systemic therapy rarely indicated

Infection Related Dermatoses

Eczema herpeticum

Staphylococcal scalded skin syndrome

Rocky Mountain spotted fever

Necrotizing fasciitis

Eczema Herpeticum

- Synonym – Kaposi varicelliform eruption
- Widespread HSV infection within atopic dermatitis
- Population – individuals with underlying atopic dermatitis (infants, children more common)
 - Can appear in other dermatoses and areas of skin breakdown
- Cause – HSV types 1 or 2
 - Typically occurs with first outbreak, recurrences are uncommon
 - Variants – eczema coxsackium (hand foot mouth disease), disseminated vaccinia (smallpox vaccine)

Eczema Herpeticum – Presentation

- Fever, malaise, LAD common
- Lesions may appear and spread over 7-10 days
- Clusters of monomorphic painful vesicles, some with umbilication, that progress to crusted erosions over several weeks
- Impetiginization common, especially around nose and mouth
- Ocular involvement possible when periorbital region involved and requires emergent management by Ophthalmology



Eczema Herpeticum – Management

- Admission typically not required, but depends on symptoms and if underlying immunosuppression
- Urgent management with antivirals
 - Acyclovir 400-800mg 5 times daily x10-14 days
 - Valacyclovir 1g BID x10-14 days
 - IV Acyclovir 15mg/kg/d if admitted
- Management of impetiginization with antibiotics
- Topical steroids for symptoms control (only ok to use once antivirals are initiated)

Staphylococcal Scalded Skin Syndrome (SSSS)

- Acute cutaneous reaction to *S. aureus*
- Population – infants and children (most common), may occur in adults with CKD and immunosuppression
 - Adults develop antibodies to exotoxins and therefore SSSS is rare unless immunocompromised or renal failure
- Cause – *S. aureus* infection of the skin/throat/ears/eyes releases two epidermolytic exotoxins A and B which target desmoglein 1 in desmosomes
 - Desmosomes form connections between keratinocytes in the epidermis → targeting of desmoglein causes breaks in the connections between keratinocytes resulting in desquamation of the epidermis
- Mortality - <5% in children, ~60% in adults

SSSS – Presentation

- Fever
- Erythema with tissue paper-like wrinkling of skin in armpits, groin, and around orifices → flaccid bulla and desquamation spreads to arms, legs, trunk leaving exposed moist red tender skin
- Nikolsky sign positive – sheering of epidermis from underlying dermis with rubbing of skin



SSSS – Management

- Hospital admission – IV antibiotics, fluid/electrolyte/thermal/nutrition management
 - IV antibiotics can be transitioned to oral antibiotics after few days depending on response
 - Topical antibiotics are not sufficient
- Penicillinase-resistant anti-staphylococcal antibiotics – flucloxacillin, nafcillin, oxacillin, cephalosporin, clindamycin, vancomycin
- Systemic steroids – contraindicated as they slow healing
- Adults – IVIg, plasma exchange
- Supportive – pain management, skin care with emollients and non-adherent dressing
- Data limited on dialysis as part of treatment in CKD, but should be considered
- Data limited on holding immunosuppressive agents, but should be considered

Question 5

Which of the following is false in staphylococcal scalded skin syndrome (SSSS)?

- A. SSSS is more common in children compared to adults
- B. SSSS is caused directly by staphylococcal bacterial infection in the skin
- C. SSSS is caused by the exfoliative toxin produced by phage group II strains of *S. aureus* which targets desmosomes in keratinocytes
- D. Treatment should include hospitalization for IV penicillin and wound care

Rocky Mountain Spotted Fever (RMSF)

- Tick-borne bacterial infection resulting in blood vessel damage in multiple tissues and organs
- Population – any age or gender, more common in children
- Cause – *Rickettsia rickettsia*
- Vector – Dermacentor tick (must be attached >24 hours)
- Location – US, Canada, Mexico, South America
- Time – spring, summer
- Mortality – 1-4%, higher in <5yo and >70yo

RMSF – Presentation

- Onset within 14 days of tick bite
- Fever and severe headache followed by rash 2-5 days later
- Myalgias
- Abdominal pain, nausea, vomiting
- Confusion, lethargy

RMSF – Skin Presentation

- Appears around days 3-5
- Small (1-5mm) erythematous pruritic macules → progress to erythematous papules and petechiae → may become hemorrhagic and crusted or necrotic
- Begins on ankles and wrists then spreads to palms and soles then spreads centrally to the trunk, may spread to face but face usually spared
- With resolution, skin may desquamate or scar



RMSF – Complications

- Seizures
- Blindness, deafness
- Coma
- Damage to lungs, heart, kidneys, liver

RMSF – Management

- Serology – indirect fluorescent antibody test against rickettsial antigens is typically positive 10-14 days after infection
- Clinical – if suspicion is high, initiate treatment even if diagnosis is not yet confirmed
- Treatment – initiate Doxycycline 100mg BID and continue until absence of fever >2-3 days
 - Doxycycline is TOC even in children <8yo in RMSF
 - Pregnancy – Chloramphenicol

RMSF – Prevention in High Risk Areas

- Avoid forests and fields where ticks reside
- Wear long-sleeve shirts and pants that fit tightly around wrists, ankles and waist
- DEET insect repellents on skin, Permethrin on clothes
- If in exposed area, check skin twice daily
- Removal of tick – use gloves, grasp tick as close to skin as possible with tweezers and gently pull out

Necrotizing Fasciitis

- Severe rapidly spreading bacterial infection of soft tissue and fascia resulting in vascular occlusion and necrosis of tissue with possible rapid progression to septic shock, multiorgan failure and death
 - Infection starts in superficial fascia then spreads horizontally through fascial plane before spreading vertically to overlying skin and underlying muscle → diagnosis may be delayed due to initial horizontal spread
 - Mortality up to 25%
- Can involve any location
 - Leg most common site
 - Fournier gangrene – perineal, genital, perianal → 15-50% mortality rate
- Risk factors – advanced age, obesity, DM, chronic illness, malignancy, immunosuppression, ASA/NSAIDs, drug abuse

Necrotizing Fasciitis

Type I

- Polymicrobial – S. aureus, Haemophilus, vibrio, E.coli
- Older patients, diabetics, other comorbidities

Type II

- Hemolytic group A strep or staph (including MRSA)
- All ages
- Can involve healthy individuals

Type III

- Clostridium perfringens or septicum
- Injury, surgery, IV drug abuse
- Crepitus – gas within skin causes crackling

Fungal organisms

- Traumatic wounds
- Immunocompromised

Marine organisms

- Wounds by seawater, cuts by fins/stingers, consumption of raw seafood
- Liver disease
- Can be fatal within 48 hours

Necrotizing Fasciitis – Presentation

- Symptoms appear within 24 hours of injury with clinical features taking 3-4 days to appear
- Pain out of proportion to appearance that progressively worsens
- Flu-like symptoms
- Intense thirst common
- Site of infection – violaceous and edematous → duskiness with development of hemorrhagic and necrotic bulla → necrosis
 - Crepitus present due to gas within tissue
 - Severe pain followed by anesthesia due to necrosis involving sensory nerves



Necrotizing Fasciitis – Aggressive Progression

- Even with immediate antibiotic intervention, infection may not improve
- Within 4-5 days – high fevers, hypotension → septic shock and multiorgan failure
- Spread of abscesses to liver, lung, spleen, brain, pericardium, skin

Necrotizing Fasciitis – Management

- Diagnosis primarily clinical
 - Finger test – 2cm incision made in skin and index finger inserted → nec fasc confirmed if finger progresses with no resistance
- Labs – WBC $>15.4 \times 10^9/L$, sodium $<135 \text{mmol/L}$, CRP $>16 \text{mg/dL}$, CK $>600 \text{U/L}$, urea $>18 \text{mg/dL}$
- Blood culture
- Deep tissue biopsy with gram stain and tissue culture to determine bacterial or fungal species
- Imaging – xray, CT, MRI → can identify gas in tissues

Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC)

- Can assist in distinguishing nec fasc from other infections
- Score of 6+ rule in nec fasc
- Score <6 does not completely rule out nec fasc

Variable	Unit	Score
C-reactive protein	mg/dL	
<15		0
≥15		4
WBC	per mm ³	
<15,000		0
15,000–25,000		1
>25,000		2
Hemoglobin	g/dL	
>13.5		0
11.0–13.5		1
<11.0		2
Na	mmol/L	
≥135		0
<135		2
Creatinine	mg/dl	
≤1.6		0
>1.6		2
Glucose	mg/dL	
≤180		0
>180		1

Necrotizing Fasciitis – Management

- ICU admission
- Supportive measures – oxygen, fluids, blood pressure management
- High dose IV antibiotics while awaiting tissue culture results
 - Penicillin, clindamycin, metronidazole, cephalosporins, carbapenems, vancomycin, linezolid
- Transition to high dose IV antibiotics specific to tissue culture results as soon as possible
- Urgent surgical debridement of all infected and necrotic tissue repeated frequently as disease progresses
 - Skin grafting usually required after infection completely cleared
- Hyperbaric oxygen therapy
- IVIg


Immunobullous Exacerbations

Bullous pemphigoid
Pemphigus vulgaris


Bullous Pemphigoid

- Chronic autoimmune bullous disease
- Population – >50yo, classically in elderly
- Causes – drug, injury, infection, unknown
 - PD1-inhibitors (chemotherapeutic), dipeptidyl peptidase-4 inhibitors (gliptins for DM), antibiotics, penicillamine, potassium iodide, furosemide, captopril, gold, topical flurouracil
- Pathogenesis – antibodies against BP180 (type XVII collagen) in the hemidesmosomes of the cutaneous basement membrane zone
 - Destruction of hemidesmosomes causes separation of the epidermis from the dermis (subepidermal bulla) which are tense


A Normal skin



B Pemphigus vulgaris



C Bullous pemphigoid



- Antibody to desmosomal proteins
- Antibody to hemidesmosomal proteins

BP – Presentation

- Erythematous pruritic plaques develop tense bulla that rupture with crusting, hyperpigmentation and areas of scarring
- Flexor surfaces and intertriginous regions common but can generalize
- Mucosal involvement uncommon




BP – Management

- Milder disease can be managed outpatient while more severe cases need admission to initiate management and monitor for complications such as secondary bacterial or viral skin infection
- Diagnosis – skin biopsy of early blister for H&E and DIF
- Treatment
 - Prednisone – 0.5-1mg/kg/d for several weeks (until no new blisters develop) then prolonged gradual taper over months
 - Ultrapotent topical steroids (Clobetasol)
 - Doxycycline 100mg BID
 - Initiation of steroid sparing agents while tapering prednisone – dapsone, methotrexate, nicotinamide, azathioprine, mycophenolate, IVIg, Rituximab
 - Analgesics
- Referral to Dermatology for continued management


Pemphigus Vulgaris

- Chronic autoimmune bullous disease
- Population – most commonly 30-60yo
- Causes – unknown, malignancy, infection, trauma, drug
 - Drug-induced – penicillamine, ACE-inhibitors, ARBs, cephalosporins
- Pathogenesis – antibodies against desmoglein 3 in desmosomes between keratinocytes in the lower epidermis
 - Destruction of desmosomes causes separation between keratinocytes in the lower epidermis (intraepidermal bulla) which are flaccid
- Mortality – 5-15%


A Normal skin



B Pemphigus vulgaris



C Bullous pemphigoid



- Antibody to desmosomal proteins
- Antibody to hemidesmosomal proteins

PV – Presentation

- Mucosal involvement classically presents first followed by cutaneous involvement few weeks later
- Mucosa – oral erosions, pharyngeal/laryngeal erosions cause painful swallowing and hoarseness, nasal erosions cause congestion and bleeding, erosions of conjunctiva, esophagus, labia/vagina/cervix, penis, urethra, anus
- Cutaneous – flaccid thin-walled erythematous bulla that easily ruptured causing painful and pruritic erosions with scaling and crusting, most commonly on upper chest, back, scalp and face



PV – Management

- Milder disease can be managed outpatient while more severe cases need admission to initiate management and monitor for complications such as secondary bacterial/viral/fungal skin infection and malnutrition due to decreased PO intake
- Diagnosis – skin biopsy of early blister for H&E and DIF
- Treatment
 - Prednisone – 0.5-1mg/kg/d for several weeks (until no new blisters develop) then prolonged gradual taper over months
 - Ultrapotent topical steroids (Clobetasol)
 - Initiation of steroid sparing agents while tapering prednisone – azathioprine, mycophenolate, cyclophosphamide, rituximab, dapsone, methotrexate, doxycycline, IVIg, extracorporeal photopheresis, plasmapheresis
 - Gentle wound care, non-adherent bandages, emollients, antimicrobial washes, analgesics, oral swish-and-spit steroids and analgesics
- Referral to Dermatology and Ophthalmology for continued management

References

- Bologna JL, Schaffer JV and Ceroni L. (2018). Dermatology, 4th Ed.
- Cribier B, Piemont Y and Grosshans E. (1994). Staphylococcal scalded skin syndrome in adults. *JAAD*;30(2):319-324.
- Husain Z, Reddy BY and Schwartz RA. (2013). DRESS Syndrome Parts I and II. *JAAD*;68(5):693.e1-e14 and 709.e1-e9.
- <https://dermnetnz.org/topics/erythema-multiforme>
- <https://dermnetnz.org/topics/stevens-johnson-syndrome-toxic-epidermal-necrolysis>
- <https://dermnetnz.org/topics/drug-hypersensitivity-syndrome>
- <https://dermnetnz.org/topics/acute-generalised-exanthematous-pustulosis>
- <https://dermnetnz.org/topics/eczema-herpeticum>
- <https://dermnetnz.org/topics/staphylococcal-scalded-skin-syndrome>
- <https://dermnetnz.org/topics/rocky-mountain-spotted-fever>
- <https://dermnetnz.org/topics/necrotising-fasciitis>
- <https://dermnetnz.org/topics/bullous-pemphigoid>
- <https://dermnetnz.org/topics/pemphigus-vulgaris>